PROVECTUS PHARMATECH, INC.;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.;H‧李‧墨菲特癌症中心和研究機構股份有限公司
A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.
